COLUMBUS CHILDREN’S FOUNDATION AND PHOENIX NEST BIO PARTNER TO ACCELERATE GENE THERAPY FOR SANFILIPPO SYNDROME TYPE C

Organizations unite with world-class scientific and AAV technology leaders to find a cure for life-altering and fatal ultra-rare disease

Brooklyn, NY and Raleigh, NC (Oct 28, 2020)—Phoenix Nest, a New York based biotechnology company will partner with Columbus Children’s Foundation (CCF) to advance the development and manufacturing of a potential gene therapy treatment for Sanfilippo syndrome type C, an ultra-rare metabolic disorder, also referred to as MPS IIIC. 

It is estimated that only 1 in a million children are born with MPS IIIC with less than 500 children worldwide known to have this devastating disease. Individuals affected by this type of Sanfilippo syndrome lack a single enzyme necessary to break down long chains of sugar molecules called mucopolysaccharides (also known as glycosaminoglycans or GAGs). These GAGs are left to build up in every cell of the body causing catastrophic effects to the CNS and throughout the body. Children appear normal at birth and it isn’t until the children fail to meet typical milestones that parents become worried. As the disease progresses, children lose all their skills including the ability to talk, walk, and swallow. The disease is terminal and there is no current treatment.

“MPS IIIC, like many ultra-rare diseases, is not being addressed by large biotech and pharma companies due to small patient populations and the significant investment required for research, development and manufacturing,” commented Laura Hameed, Columbus Children’s Foundation managing director. “This is the basis for our mission and the formation of a nonprofit biotech foundation focused on accelerating development and access to curative gene therapies for children with ultra-rare genetic conditions at an more affordable cost that does not lead to access issues.”

Phoenix Nest founder and Chief Financial Officer, Jill Wood, is a fierce patient advocate and mother whose son Jonah, along with approximately 500 children around the world, suffer from this rare condition.  Jill, along with her husband Jeremy Weishaar and a renowned scientific advisory board, have facilitated and funded research for potential enzyme replacement therapies (IIID), chaperone therapy (IIIC) and stem cell/gene therapy (IIIB).

According to Ms. Wood, “Like many small biotechs, we lack the funding and expertise to advance potential treatments and cures for this devastating disease, but we know a cure is in sight. Working collaboratively with the Columbus Children’s Foundation, we will gain access to world-class scientific and manufacturing expertise, saving millions of dollars and time, a luxury my son Jonah and many children like him do not have.”

The partnership between CCF and Phoenix Nest is a leading example of the effort needed to bridge the translational gap that slows or impedes many rare disease programs with curative potential. The nonprofit biotechnology foundation model pioneered by CCF plays an important role in the rare disease ecosystem by partnering with leading researchers and contract development and manufacturing organizations (CDMOs). These include companies such as Viralgen Vector Core, a leading manufacturer of adeno-associated virus (AAV) medicines, and Asklepios BioPharmaceutical (AskBio), a company revolutionizing life-saving gene therapeutics and genetic medicine technology.

“This is the third program we will put into development or manufacturing in the last two months,” according to Hameed. “This partnership reflects exceptional progress toward our goal of accelerating treatments for programs that are scientifically promising, but not commercially viable. We believe no child should be left behind when cures are in reach and are thrilled to partner with organizations like Phoenix Nest to advance our mission to bring gene therapy cures to children with the urgency they deserve.”

About Columbus Children’s Foundation (CCF)

CCF’s mission is to ensure equitable and affordable access to the most effective gene therapy solutions for children with ultra-rare genetic diseases. CCF uses a nonprofit model to partner and accelerate gene therapy treatments for programs with very small patient populations that are often overlooked because the economics don’t add up for those using a traditional commercial development model. Through strategic partnerships with other foundations, industry leaders, patient groups and philanthropic donors; CCF aims to bring the scientific and funding resources together on behalf of the children and families who must endure the devastating outcomes of ultra-rare diseases. CCF accelerates hope and transforms the lives of those fighting these devastating diseases.  Learn more at www.columbuschildren.org 

About Phoenix Nest

Phoenix Nest is a bespoke virtual biotech with one mission, to provide a treatment for the children suffering from Sanfilippo syndrome. Founded by a mother of a Sanfilippo child, Phoenix Nest has sponsored various research initiatives with leading scientists and medical experts to find treatments and cures for all types Sanfilippo syndrome. Led by parents of children with Sanfilippo syndrome, the company operates first and foremost in the best interest of children in critical need for a cure. http://www.phoenixnestbiotech.com/

COLUMBUS CHILDREN’S FOUNDATION AND CURESPG50 ANNOUNCE MANUFACTURING PARTNERSHIP FOR AAV GENE THERAPY

Toronto, Canada and Raleigh, NC (Sept 15, 2020)—CureSPG50, a Toronto based charity with the mission to develop a cure for the ultra-rare disease Spastic Paraplegia 50 (SPG50) and Columbus Children’s Foundation, a non-profit biotech foundation with the mission to accelerate access to the most effective gene therapy cures for children with ultra-rare diseases, announce a strategic partnership related to accelerating the production of AAV vector needed to advance the curative treatment into the clinic.

Columbus Children’s Foundation (CCF), is a nonprofit biotech known for its translational role in the acceleration of gene therapy programs bringing hope to children with ultra-rare genetic diseases. In addition to advancing its internal programs for ultra-rare diseases, CCF partners with contract development and manufacturing organizations (CDMOs) such as Viralgen Vector Core (VVC), a leading manufacturer of Adeno-associated virus (AAV) vectors for gene therapy, to provide expertise, access to capacity and significantly discounted Adeno-associated viral vector (AAV) manufacturing for ultra-rare diseases for which there’s limited commercial therapeutic availability.

CureSPG50 is a parent driven foundation founded by Terry Pirovolakis and his wife Georgia to find and advance a cure for their youngest son Michael, as well as the more than 60 other children worldwide diagnosed with the ultra-rare, neurodegenerative disease – Spastic Paraplegia 50 (SPG50). SPG50 is robbing them of the ability to use their limbs and severely affects and degrades their mental capacity. Michael was diagnosed with the disease as an infant and at the time doctors said there was no treatment available and advised both Terry and Georgia that the best they could do was to go home and love their child. As parents they could not sit back and watch Michael deteriorate, instead they decided to search the world for a cure. The mission of CureSPG50 is to help children affected by SPG50 and other neurodegenerative diseases by leveraging Gene Replacement Therapy to replace the defective gene with a working one.

“As parents we are willing to do anything, go anywhere and give up everything to save our child,” says Found Terry Pirovolakis.

Together the partnership between CCF and CureSPG50 is a leading example of the effort needed to bridge the translational gap that slows many programs in the field of rare diseases through leveraging critical translational and manufacturing expertise while also addressing the economic accessibility issues that nonprofit ultra-rare drug development programs face, especially for scientifically promising yet not commercially viable programs such as the development of an AAV gene therapy exemplified in this collaboration.

“The partnership with CCF will allow us to work quickly for a gene therapy cure and in a manner that stays within our original budget to save children affected by SPG50. Due to Covid-19, many biotechnology companies around the world have been impacted by serious delays and those that are available to manufacture a drug such as ours have significantly increased costs or simply lack the necessary expertise. We have been given a golden opportunity to save our children with great speed rarely seen in the rare disease sector thanks to CCF and Viralgen,” says Terry Pirovolakis.

This partnership with CCF is driving the CureSPG50 vision to be realized through cost savings of several million dollars over typical commercial costs and over 12-24 months of time savings. Manufacturing is one of the most difficult steps of this process and working with an industry leader is helping to close the rare disease divide for families and for children with ultra-rare diseases. Working with CCF and their partners, like VVC, also offers access to critical strategic support and expertise from leaders within the AAV field on behalf of programs that are held back by not having that expertise readily available.

“CCF is deeply driven by the urgency to ensure equitable access to the most effective treatments for patients with ultra-rare diseases. We believe no children should be left behind when cures are in reach and are thrilled to partner with organizations like CureSPG50 to effectuate that mission. I am inspired daily by parents, like Terry and Georgia, who have effectively become citizen scientists as they seek treatments for their child. We aim to ensure that the translational gap is bridged so that promising programs can move forward to become cures that save the lives of children,” remarked CCF executive director, Laura Hameed.

Through these partnerships, Columbus Children’s Foundation is working towards establishing an ecosystem that society can use to develop therapeutics for ultra-rare diseases using a nonprofit approach that has both science and compassion at its core. Today, with this announcement, we are one step closer to the goal of working towards the eradication of all diseases, even those with ultra-small patient populations.

About CureSPG50

CureSPG50 is a Toronto-based charity founded by Terry and Georgia Pirovolakis after their youngest child Michael was diagnosed with Spastic Paraplegia 50, an ultra-rare genetic disease as a toddler.
Michael is the only child in Canada currently known to have the disease. CureSPG50’s mission is to find a gene therapy cure for SPG50 so that no child currently born, and those in the future, will ever suffer from its terrible effects. With the incredible collaboration from world leading researchers from Cambridge University, Boston Children’s Hospital, Harvard University, UT SouthWestern Medical Centre and the National Institute of Health, a cure is within reach. With the support of tens of thousands of donors from across the world, CureSPG50 has been able to fund this remarkable research and do what was deemed impossible – change the lives of children affected by SPG50.
Learn more at www.CureSPG50.org

About Columbus Children’s Foundation (CCF)

CCF’s mission is to ensure equitable and affordable access to the most effective gene therapy solutions for children with ultra-rare genetic diseases. CCF uses a nonprofit model to partner and accelerate gene therapy treatments for programs with very small patient populations that are often overlooked because the economics don’t add up for those using a traditional commercial development model. Through strategic partnerships with other foundations, industry, patient groups and philanthropic donors; CCF aims to bring the scientific and funding resources together on behalf of the many ultra-rare diseases to accelerate hope and transform the lives of those fighting these devastating diseases.
Learn more at www.columbuschildren.org

Dr. Krystof Bankiewicz — World Renowned Gene Therapist — Named President and Chief Executive Officer, Columbus Children’s Foundation

Columbus Children’s Foundation announced today that Krystof Bankiewicz, M.D., Ph.D., has been named president and chief executive officer. Dr. Bankiewicz will work closely with Executive Director Laura Hameed and CCF’s esteemed board of trustee members, the CCF Cures Cabinet, and scientific advisors. 

Bankiewicz, founder of multiple biotech companies and tenured professor in the Department of Neurosurgery at The Ohio State University College of Medicine, has been instrumental in the organization’s success by developing and delivering multiple life-changing treatments as a CCF founding trustee. 

According to CCF Chairman and Chief Science Officer R. Jude Samulski, “Dr. Bankiewicz has been quietly focused on bringing life-saving medicines to children that have shown tremendous therapeutic outcomes. He is a remarkable talent with a sincere focus on using his expertise to change the lives of children with significant unmet medical needs. We’re thrilled to see someone with his mindset, expertise, and experience join us in this leadership role. Our organizational mission is aimed at ensuring no children are left behind when science can put cures in reach and Krystof will be a key player in effectuating that mission.” 

In this new role, Bankiewicz will orchestrate CCF’s unique non-profit model for conducting translational research and developing pre-clinical and clinical novel therapeutic programs to advance treatments for children with ultra-rare, and often debilitating, genetic disorders. 

“The significant impact Dr. Bankiewicz has had on the field of neuro-restorative medicine and gene therapy raises the Foundation’s standing and its ability to accelerate curative solutions will help children around the globe,” said Hameed. “Additionally, this innovative approach has the potential to change the market through developing cures while also ensuring equitable and affordable access for treatments. Access to cures without affordability creates tragic equity and access issues and I am thrilled that he has chosen to advance treatments using this innovative model. This approach brings out the best in science and humanity.” 

“In a world where economics do not add up for large biotech or pharmaceutical organizations to develop genetic medicine for smaller populations of children with ultra-rare conditions, by accelerating these programs in this manner, we can bring the focus needed to give these kids and their families a chance at life,” said Bankiewicz. “Achieving the astounding results we are seeing in children who have already been treated and joining the Foundation to expand this impact is one of the most rewarding opportunities of my career. I look forward to doing my part to make a difference in children’s lives and advance the ability to impact advancement in gene therapy more broadly.”

Recognized in the medical community for groundbreaking accomplishments treating Parkinson’s Disease and other conditions affecting the central nervous system, Dr. Bankiewicz pioneered delivery of gene therapeutics directly to the brain to treat neurological disorders. Among his many achievements as an industry and academic leader, he co-founded three companies, invented numerous medical patents and is author to more than 230 peer-reviewed research articles. Bankiewicz is a tenured professor of neurosurgery and Gilbert and Kathryn Mitchell Endowed Chair at The Ohio State University College of Medicine. Prior to that, he served as Kinetics Foundation chair in translational research and tenured professor in residence of neurological surgery and neurology at the University of California San Francisco. 

Bankiewicz earned an M.D. from Jagiellonian University in Krakow, Poland, and a Ph.D., D.Sc., from the Institute of Neurology and Psychiatry in Warsaw. He also trained at National Institutes of Health in Bethesda, MD. 

Cure Rare Disease Announces Partnership with Columbus Children’s Foundation

Companies Unite in an Effort to Drive the Development of Drugs for Rare Diseases Globally

Boston, Massachusetts–(Newsfile Corp. – August 19, 2020) – Cure Rare Disease (CRD), the emerging, Boston-based nonprofit on a mission to develop customized therapeutics for rare diseases, announced a strategic partnership with Columbus Children’s Foundation (CCF), a nonprofit biotech known for its role in the advancement and acceleration of gene therapy programs bringing hope to children with ultra-rare genetic diseases. In addition to advancing its internal programs for ultra-rare diseases, CCF is partnering with contract development and manufacturing organizations (CDMOs) such as Viralgen Vector Core (VVC), a leading manufacturer of Adeno-associated virus (AAV) vectors for gene therapy, to provide, expertise, access to capacity and significantly discounted Adeno-associated viruses (AAV) for ultra-rare diseases and mutations for which there’s limited therapeutic availability.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways

  • Cure Rare Disease is partnering with Columbus Children’s Foundation to address the economic accessibility issues that nonprofit ultra-rare drug development programs face.
  • Manufacturing is one of the most difficult steps and CCF is helping to close the rare disease divide.
  • Working with CCF and their partners, like VVC, offers access to support in the AAV field, paired with a high-quality product that’s being produced for the first custom treatment for Duchenne muscular dystrophy pending FDA approval.
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/62033_reportablesimageresized5.jpg

Select image to view the full announcement, including downloadable images, bios, and more.

About Cure Rare Disease (CRD)

CRD is a Boston-based nonprofit biotechnology company founded by Rich Horgan, Blavatnik Life Science Entrepreneur-in-Residence at Harvard Business School who has witnessed three generations of his family affected by Duchenne muscular dystrophy, a fatal, neuromuscular disease. As anyone who is touched by a fatal, rare disease knows, time is of the essence. To overcome the obstacles inherent in the existing model of drug development, CRD has taken a new approach, forming an unprecedented collaboration with leading researchers and institutions nationwide in genetics, genomics, bioinformatics and biotechnology. Horgan and team are pioneering the development of a new platform for customized therapeutic treatments that can be applied to a range of rare, genetic diseases, and aim to inspire hope for a cure. Learn more at www.cureraredisease.org.

About Columbus Children’s Foundation (CCF)

CCF’s mission is to ensure equitable and affordable access to the most effective gene therapy solutions for children with ultra-rare genetic diseases. CCF uses a nonprofit model to partner and accelerate gene therapy treatments for programs with very small patient populations that are often overlooked because the economics don’t add up for those using a traditional commercial development model. Through strategic partnerships with other foundations, industry, patient groups and philanthropy; CCF aims to bring the scientific and funding resources together on behalf of the many ultra-rare diseases to accelerate hope and transform the lives of those fighting these devastating diseases. Learn more at www.columbuschildren.org

Contact:

Nina Pfister
nina@mooringadvisorygroup.com
781-929-5620

Cell & Gene Therapy Insights: Curing ultra-rare diseases while ensuring access, equity and affordability

By definition, rare diseases are rare. Yet, while individual diseases may be rare and only affect a small population, the total number of people living with a rare disease is quite large. Surprisingly, if you amalgamate all the people living with the more than 7,000 known rare diseases, the population would be larger than the third most populous country in the world. And, one out of two patients diagnosed with rare disease is a child.

Read the full editorial article by R. Jude Samulski, Chairman, Chief Science Officer at Columbus Children’s Foundation & Laura Hameed, Executive Director at Columbus Children’s Foundation here.

Solidarity concert at the Prado National Museum

December 11, 2019

8:30 pm – 10:00 pm

Museo Nacional del Prado, Calle de Ruiz de Alarcón, 23 Madrid , 28014 Spain + Google Map

The Columbus Foundation, in collaboration with the Museo Nacional del Prado, has organized a solidarity concert on the occasion of its second anniversary. An exquisite and extraordinary experience that will take place next Wednesday, December 11, at 8:30 p.m. at the Museo Nacional del Prado, within the framework of its Bicentennial.

From the Columbus Foundation we combine art and science with the goal of saving lives. For this special event, we have the generous participation of great internationally renowned artists:

  • María José Montiel, mezzo-soprano
  • Iván Martín, piano
  • Ángel Luis Quintana, accompanied by the cello ‘Il Soldato’
  • And the space collaboration of Dr. Toni Pearson, at the piano

All tickets are sold for the charity gala, but  you can collaborate with FILA 0, through IBERCAJA: ES15 2085 9366 1303 3033 9645 or the donations section of the website .

Details

Date: December 11

Hour: 8:30 pm – 10:00 pm

Organizers

Columbus Foundation

Want Foundation

Place

National Prado Museum

Calle de Ruiz de Alarcón, 23
Madrid , 28014 Spain + Google Map

Web page: https://www.museodelprado.es/

A successful operation in Varsovia

Four year old Irai had a rare disease that only affected around 130 children worldwide –  aromatic amino acids decarboxylase (AADC) deficiency, also known as Juvenile Parkinson’s. It is a genetic neurological disorder that affects the brain’s ability to produce neurotransmitters, specifically dopamine and serotonin, the most crucial ones for daily life. The lack of this protein results in a disconnection between the brain and her body with all of the consequences this implies.

Irai is the first Spaniard to receive gene therapy treatment to cure her rare disease. This is thanks to the Columbus Children’s Foundation which has pioneered a revolutionary project in Europe these past months. The objective is to treat children with rare neurodegenerative diseases, the first of which is the aromatic amino acid decarboxylase (AADC) deficiency.

Since the success of the clinical trials in the USA in 2017 in collaboration with the Ohio State University and the University of California San Francisco (UCSF), the first cases that have been treated in Varsovia have already proven to be a great success. Amongst them is also the success of Irai’s treatment.

The gene therapy treatment

On May 14th,  Irai was treated successfully in the Interventional Neurotherapy Centre of Brodno in Poland. The work of the medical team led by Dr. Krystof Bankiewicz, a gene therapy specialist and resident professor of neurological surgery in the UCSF, made all of this possible. Irai has been a tireless fighter since she was born. Until now, she wasn’t able to hold her head upright. She couldn’t sit down or use her arms or legs. She couldn’t speak, and she frequently suffered from painful episodes of neck tension linked with the diversion of her eyes called oculogyric crises.

A few weeks after the operation, the little girl’s development has been encouraging, and she has been experiencing the expected post-operation symptoms. These include spontaneous movements, insomnia, etc. In addition, the medication that she previously took to treat the condition has been gradually reduced. This is a large step for her and her family.

“Irai’s spontaneous movements have been decreasing, and it is truly impressive how she copes without complaints. She is also now able to be on the floor, which is great for her psychomotor development,” explains her mother, Carolina.

Replacing the missing gene

Despite having difficulty with sleeping and a significant reduction in sleeping time, all of the symptoms are good signs. “Her body is receiving the dopamine it was missing and that it wasn’t used to – this means that the operation was a success,” comments the president of the Columbus Foundation, Damià Tormo.

Gene therapy is a type of treatment that uses genes to treat or prevent diseases allowing the insertion of a gene into the cells of a patient instead of having to medicate or operate in order to treat the disorder. “The therapy aims to return to these children the information that they were missing when they were born,” points out Tormo.

Marta fights for a cure

Marta is a four-and-a-half-year-old girl with Niemann Pick C. This is a rare neurodegenerative genetic disease that she was diagnosed with in its most severe form: that of childhood early onset. Despite the hardships of her daily life, Marta has decided to embark on a voyage to find a cure, with the hope and support of her parents and hand in hand with the Columbus Foundation. Ignacio is her father. We spoke to him so that we could learn a little bit more about Marta and the initiative ‘The voyage of Marta’, that alongside Ana, his wife, they created. The initiative begins on the 27th of September with a charity evening in Madrid.

The disease of Niemann Pick C (NPC) is a rare genetic neurological illness. Due to a defect in the DNA, the proteins required for the transport of cholesterol are not produced resulting in its accumulation inside the cells. The failure to remove the cholesterol causes structural damage and the functional inability of these cells. Core organs are affected such as the lungs, liver, spleen, and neurons. The organism progressively deteriorates causing serious neurological damage.

When did you know about the diagnosis?
She was diagnosed when she was two months old. In a routine check-up, the pediatrician saw that her liver and spleen were swollen. He recommended we hospitalized her for 10 days in the University Hospital in Brussels. Here, they ran many tests including a procedure where she was put to sleep with anesthesia so that the doctors could obtain samples from different parts of the body. As the days went by, they ruled out more and more diseases that were less severe, and everything seemed to point towards the worst diagnosis of all, Niemann Pick C.

During these past four years, we have learned from other cases that we have seen that we were incredibly lucky to have had such a fast diagnosis and that the doctors were able to give this rare disease a full name.

What solutions were you given when Marta was diagnosed?
To be honest, we can’t remember it well. That time was extremely hard. We didn’t understand anything and we couldn’t believe that this was happening to us. Everything became even more complicated as we were living abroad, we had no family close by, and because we didn’t know what resources we could access to understand the disease better and try to cure it.

At the hospital, they had already told us there was no cure, but that there was a medication that would help to delay the development of the disease. They encouraged us to enjoy her as a baby, as her symptoms wouldn’t be as severe and obvious then as they would be in the future.

How does the illness affect the child on a daily basis?

 Unfortunately, it gets worse every day. As it’s a degenerative disease, she is progressively losing the few skills that she has developed until now. It was always very difficult for her to eat, move, learn, and do all the things that children her age usually do, even just to crawl or walk. Today, she can’t stand up or eat by herself, her diet is primarily soft foods that she can swallow. The activities that she can do are limited to those that can be done when she is sitting down.

It must be extremely hard for parents to see their child so fragile….
At the same time though, Marta never stops smiling and she loves to sing. She admires her sisters. She laughs a lot when she sees them and with some help, she plays at making food and being at the shops … ‘working’ as she likes to say, as she turns the pages of a book, but always with help. She can also understand different languages, due to the surroundings of where we live and the school for children with special needs. She is able to communicate and join three words to tell us what she wants, what she does at school and the little things in her daily life. We have two other daughters, one is older; Mencia, and the other younger one; Maria, and despite trying to live a normal life, it is increasingly harder for them as they become more aware of what is happening.

That must have a significant impact on the family.
We feel helpless as we see her worsen and we can’t do anything to prevent it. She takes so many medications and we have to be continuously aware of her every need. However, it is also true that we have learnt to think relatively and have a more profound outlook on life. We appreciate everyday as if it were a gift. All the other things that our daughters can do they observe and appreciate a lot more because they know that other children can’t do them and that teaches them to be better people and help those that need it the most.

We work and fight every day to try and see all the good things that come with Marta and with NPC, because we know that tomorrow those things will be a little diminish, so we don’t stop to suffer instead we enjoy every moment.

What solutions are there to treat this rare disease, or to alleviate the symptoms?
Currently, there are no cures for this disease. There only exists a medication called Miglustat, that currently has been shown to slow down the advancement of the disease, but only for a time. Miglustat is very strong and has many side effects which we treat with other medications. Marta has 17 pills a day. In addition to the medication, we have to work tirelessly with physiotherapists, speech therapists, and other specialists.

These past few years, there are a few medications currently on trial that have been used to treat other diseases that seem as though they could help; Ursochol, an improved version of Tanganil; Efavirenz or Fingolimod. There also exist clinical trials for new medicines like Amiroclomol or Ciclodextrina. Marta is medicated with those that are less invasive and that allow her to have the best quality of life possible.

Unfortunately, none of them offer a cure and their efficacy in improving quality of life hasn’t been completely proven. They work on some patients, but not on others.

How did you come in contact with Columbus Foundation?
A little more than a year ago we met Vanessa, Geri’s mother, who is also affected by NPC. She talked with a lot of enthusiasm and hope about Damià Tormo, the president of the Columbus Foundation and his gene therapy project for other rare diseases.

We had been working with the University College London and the laboratory of the University of Oxford to help them come up with alternatives for the financing of gene therapy in European funds and we knew about the development at a laboratory-based level for NPC. We quickly understood that we could help the Foundation and the research groups in London come into contact. The Association of Niemann Pick of Fuenlabrada was also working towards this direction. We had the opportunity to meet Damià in person in the conference of families organized in the UK in September 2018. Immediately, we saw how wonderful the project was and his commitment to advancing the laboratory phase for gene therapy for NPC into clinical trials with real patients.

How do you think that gene therapy can help Marta?
We think that it can help her quality of life, it can help her mobility, and her health. Of course, we have our concerns and fears that the damages already caused are irreversible, but we also have a lot of hope, for her and for all the others suffering from NPC.

We think that gene therapy can help her improve her health. We hope that she will be able to walk again and eat by herself and that her life will be significantly less limited.

At what stage is the research?
We don’t quite know. We know that there is hope that gene therapy will reach patients soon exits, and we believe in it, but we also treat any progress with humility and respect.

What has been the most complicated moment?
Until now, the most complicated moments have been in her first year and a half of life. After the diagnosis at six months and the severe hypotonia, the most difficult aspect was ensuring she improved her overall health so that she would gain some weight and strengthen her muscles. We commenced physiotherapy sessions so that they could keep her as active as possible. On the other hand, food was a real issue, as she couldn’t absorb the food we gave her well, and we had to overfeed her in order for that to translate into grams at the end of the week.
Now, after a year, we have the impression that the illness is advancing quickly and unfortunately that it is slowly dimming her flame of life.

 And the most gratifying?
We don’t know how to explain it. She, in capital letters, brings out the best in everyone that surrounds her. It’s a constant smile and her loving gaze and admiration for everything that is around her, especially her two sisters. It’s hard to describe. She brings out the best in everything that happens to us, as well as all the love and affection we get from people, family, and friends. Having her by our side and enjoying her every day is a gift.

 What is behind ‘The voyage of Marta?
This is an initiative that aims at raising awareness of the Columbus Foundation project. Marta is our way of giving a face to the disease that is hardly known around Spain, but that is in great need of research and quick solutions.

 Like Cristóbal Columbus, the Columbus Foundation and the children with NPC embark on a project that seems impossible and defy preestablished ideas with the new world of gene therapy. Like Columbus, it is a journey that requires sponsors to finance it. This is the start of Marta’s journey. A cabin girl that is searching, through her telescope, from the crow’s nest of her boat, land ahoy!

How can people participate in this action through social media?

 To raise awareness and tell the story, we thought of visualizing it through this initiative. #yoviajoconmarta aims at promoting the concept of gene therapy to combat Niemann Pick C with the Columbus Foundation. The idea is that we join the crew of Marta’s buccaneers and all those with Niemann Pick C with a selfie. With our hands we will make a C for Niemann Pick C and Columbus, emulating at the same time the telescope from which Marta looks into the future.

What message do you have for others that may be experiencing a similar situation?

 We would like to thank Columbus Foundation and the Association for Niemann Pick. We would like to raise society’s awareness that these illnesses exist, they may be extremely rare but they are also absolutely devastating. Not enough attention and effort is being put into them which inevitably results in a worsened quality of life for those suffering from them, and we believe that it could easily be avoided with a little more attention towards the problem.

We would like to thank the people for the affection, support and collaboration that we are receiving, these are the true sails of the boat. We would like to remind people that Marta is only one face out of 100 more families in Spain that are suffering this same situation. Lastly, in relation to any type of genetic or rare disease, we would like to share this thought: say at the top of our lungs that the real miracle of humanity is to have healthy children and with genetic diseases, to be born healthy is not a guarantee, therefore just by raising awareness for the ill today, may well be a solution for many tomorrow.

Two donors make intervention possible

Yet again, it has been made possible – this time with the help of two donors. They would like to remain anonymous as what they are really interested in is being able to contribute to access to gene therapy for children with a rare neurodegenerative disease.

Ted is from Swindon, UK. Like Irai, he suffers from the aromatic amino acid decarboxylase (AADC) deficiency. Last May, he became the first English patient to undergo eight hours of brain surgery in the trustworthy hands of more than twelve medical experts in the Interventional NeuroTherapy Centre of Brodno Hospital in Warsaw, Poland.

Professor Krystof Bankiewicz, Professor Miroslaw Zabek, Dr. Jakub Onikijuk, Dr. Thomasz Pasterski and the rest of the surgical team were able to replicate with precision the pioneering gene therapy technique they used on Irai. AADC deficiency affects 130 patients worldwide and it is the reason why Ted has been in a chair for all ten years of his life.

For this disease, gene therapy replaces the enzyme that is lacking in the brain required to produce dopamine. It is injected slowly and precisely within a viral vector.

Gene Therapy was the solution

“When Ted’s parents, Sven and Zoe, said goodbye to him at the doors of the operating room, they were excited and frightened as to whether they had made the right decision leaving their 10-year-old son on an operating table. In reality, they had already made that decision a long time ago. The family knew that if Ted ever had the chance of receiving gene therapy they would have agreed,” explains Lisa Flint, the founder and general director of the AADC trust, an organization that brings together all those whom are affected by this disease. She was glad to be able to accompany the family all the way to Poland for the treatment.

Fortunately, the operation was a great success. Ted’s cheerful personality emerged after just a few hours when with a wide smile, the youngster asked his Dad for the iPad.  “It brought lots of laughter and emotional tears from his parents,” commented Flint.

With time, maybe within a month or more, the natural production of dopamine in Ted will make him experience changes in his body. All the medications he previously took will be gradually removed, and he awaits a future free from oculogyric crises and many more symptoms caused by this devastating rare neurodegenerative disease.

“Ted’s story is not the only one in the community,” comments Lisa Flint. “Already, nine children have undergone this pioneering and transformative surgery lead by Prof. Bankiewicz. Some of them had the surgery two years ago, achieving significant and surprising progress.”